Microba Life Sciences Ltd has released a press release.
Landmark GI Study Results from over 4,600 patients
Filed with ASX ·
Watch Microba Life Sciences' latest callMicroba Life Sciences (ASX:MAP) Q4 2025 Earnings Call · Replay · Jul 22, 2025Read the transcript of Microba Life Sciences (ASX:MAP) Q4 2025 Earnings Call6ix hasn’t read this filing yet.
Microba Life Sciences Limited on 6ix
Earlier from Microba Life Sciences
- Q3 FY25 Quarterly Investor Presentation & Webinar
- Q3 FY25 Quarterly Activities Report & Appendix 4C
- Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
- Appendix 4D & FY25 Interim Report
- Q2 FY25 Quarterly Investor Presentation & Webinar
Later from Microba Life Sciences
- Microba Announces Landmark GI Study Results From Over 4,600 Patients
- MetaPanel Pathogen Study Delivers Breakthrough Results
- Trading Halt
- Suspension from Quotation
- Microba secures $14.5 million to drive clinical adoption
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences